Upper Tract Urothelial Carcinoma News and Latest Research
- Lynch syndrome carriers show 4.4% urothelial cancer rate, mostly upper tract Retrospective · JCO Precis Oncol · 2026-11-14
In a registry of 3,274 genetically confirmed Lynch syndrome carriers, 144 (4.4%) developed 224 urothelial carcinomas, over half in the upper urinary tract; MSH2/EPCAM variant carriers had higher risk (HR 4.43) than those with other MMR gene variants.
Why it matters: Raises the question of whether MSH2/EPCAM carriers warrant closer urothelial surveillance than other Lynch syndrome genotypes, pending prospective validation.
- Delphi consensus of 73 UTUC experts agrees on 32 of 40 statements for non-metastatic UTUC care Guideline · Nat Rev Urol · 2026-11-13
A two-round, web-based Delphi survey of 73 international UTUC experts (urologists and medical oncologists) rated 40 statements on diagnosis, staging, and treatment of non-metastatic upper tract urothelial carcinoma. Consensus was reached on 32 of 40 statements (80%) across both rounds, offering expert-informed guidance given limited high-level evidence in this disease.
Why it matters: Offers pragmatic expert consensus to help reduce practice variability in non-metastatic UTUC, an area with limited randomized trial evidence, though it is not a formal clinical guideline.
- Single-port robotic nephroureterectomy via lower anterior access feasible in multicenter series Retrospective · Eur Urol · 2026-11-07
In 47 patients across five centers, single-port retroperitoneal nephroureterectomy with bladder cuff excision via a single extraperitoneal incision achieved 76.7% pentafecta at 12 months, with 6% grade 3+ complications and 15% recurrence at median 12.3-month follow-up.
Why it matters: Describes an emerging single-port surgical technique for UTUC; comparative data against standard approaches are still needed.
- Commentary: pathogenic germline variants in urinary tract cancers are common but often missed Review · Renal & Urology News · 2026-11-04
A commentary piece discusses evidence that pathogenic germline variants are prevalent among patients with urinary tract cancers yet frequently go undetected on standard testing pathways.
Why it matters: Underscores the gap in germline testing uptake in urothelial cancers, consistent with prior reports of low testing rates in UTUC.
- Germline testing performed in under 5% of UTUC patients in claims analysis Retrospective · JCO Oncol Pract · 2026-10-31
A nationwide claims-based analysis of 4,783 patients with newly diagnosed UTUC found only 4.5% underwent germline testing, with no increase from 2015-2023, including just 5.6% of those diagnosed before age 50 who meet guideline criteria.
Why it matters: Raises the question of whether UTUC care pathways are failing to integrate germline evaluation despite guideline endorsement for Lynch syndrome screening; claims data cannot capture reasons testing was not ordered.
- Meta-analysis links neoadjuvant chemotherapy to better survival before nephroureterectomy in UTUC Meta-analysis · Eur Urol Oncol · 2026-10-27
Pooling 30 studies (2384 patients, mostly retrospective) on neoadjuvant chemotherapy for upper tract urothelial carcinoma, pathologic complete response occurred in 11% and downstaging in 20%; neoadjuvant chemotherapy was associated with HR 0.56 for overall survival and 0.47 for cancer-specific survival versus upfront surgery.
Why it matters: Adds support for a neoadjuvant chemotherapy approach in UTUC, though most included data are retrospective and immunotherapy evidence remains limited.
- UroVysion shows modest sensitivity but high PPV for UTUC in cytology-negative patients Retrospective · World J Urol · 2026-10-20
In a retrospective study of 1,256 patients with upper tract lesions and negative urinary cytology, UroVysion FISH had 66.9% sensitivity, 82.7% specificity, and 94.0% PPV for UTUC, and was associated with high-grade disease, lymphovascular invasion, and muscle invasion.
Why it matters: Raises the question of UroVysion as an adjunct when cytology is negative, though its low NPV limits its use for ruling out UTUC.
- TROP-2 expression stays high in UTUC regardless of prior chemotherapy, unlike NECTIN-4 Retrospective · Eur Urol Open Sci · 2026-10-18
In 141 resected UTUC specimens, NECTIN-4 positivity was much lower after prior chemotherapy (9.3% vs 47% treatment-naive), while TROP-2 positivity remained near universal in both groups (97% vs 100%).
Why it matters: Suggests TROP-2 may be a more reliable ADC target than NECTIN-4 in UTUC patients previously treated with chemotherapy.
- FDG-PET/CT upstages 22% of high-risk UTUC cases beyond CT, changing treatment in 21% Retrospective · BJU Int · 2026-10-15
In a 203-patient cohort with suspected high-risk UTUC, adding FDG-PET/CT to CT led to clinically relevant stage migration in 22% of patients and altered treatment recommendations in 21%, with higher sensitivity for nodal metastases than CT (74% vs 33%).
Why it matters: FDG-PET/CT may refine staging and treatment selection in high-risk UTUC beyond conventional CT imaging.
Urology clinical trials · Urology podcasts · Urology videos · Meetings · Daily edition archive
Loading today's edition…